A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer

Hu,Qiong‑Ying; Zhao,Zi‑Yi; Li,Shui‑Qin; Li,Li; Li,Guang‑Kuo

doi:10.3892/mco.2017.1227

A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer

Authors:
- Qiong‑Ying Hu
- Zi‑Yi Zhao
- Shui‑Qin Li
- Li Li
- Guang‑Kuo Li
View Affiliations

Affiliations: Department of Laboratory Medicine, Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China, Central Laboratory, Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China, Department of General Surgery, Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China, Department of Radiology, Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China
Published online on: April 26, 2017 https://doi.org/10.3892/mco.2017.1227
Pages: 846-852
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non-coding RNAs (lncRNAs) have been identified as novel biomarkers for the diagnosis, staging and prognosis for gastric cancer. However, various studies have reported a series of significances based on different diagnostic values. Therefore, the current study performed a systematic review and meta‑analysis to evaluate the diagnostic accuracy of lncRNAs for gastric cancer, and to discuss lncRNA types and sources of heterogeneity. The Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, EMBASE, the Chinese Biomedical Literature Database, the China Academic Journals Full‑text Database and the Chinese Scientific Journals Database were systematically searched for potential studies. Studies were included if they were associated with lncRNAs, gastric cancer and reported diagnostic outcomes. Analysis of diagnostic values was used to summarize the overall test performance of lncRNAs. Ten studies were included in this meta‑analysis. The ranges of the diagnostic value of lncRNAs for gastric cancer were as follows: Sensitivity was 0.45‑0.83, and pooled sensitivity was 0.63; specificity was 0.60‑0.93, and pooled specificity was 0.75; positive likelihood ratio was 1.80‑6.92, and pooled positive likelihood ratio was 2.51; negative likelihood ratio was 0.23‑0.67, and pooled negative likelihood ratio was 0.50; diagnostic odds ratio was 3.33‑13.75, and pooled diagnostic odds ratio was 5.47. An overall area under the curve value of the summary receiver operating characteristic curve was 0.7550. LncRNAs did not have a high accuracy for identifying gastric cancer at present, but may be a useful screening tool for diagnosing gastric cancer due to their correlation with gastric cancer biological features. LncRNAs are potential biomarkers for gastric cancer if the screening strategy is altered, or they are combined with other biomarkers to diagnose gastric cancer.

View Figures

View References

1	Hsieh YH, Chiu WC, Lin CF, Chan HL, Liang HY, Lee Y, McIntyre RS and Chen VC: Antidepressants and gastric cancer: A nationwide population-based nested case-control study. PLoS One. 10:e01436682015. View Article : Google Scholar : PubMed/NCBI
2	Shin VY, Ng EK, Chan VW, Kwong A and Chu KM: A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol Cancer. 14:2022015. View Article : Google Scholar : PubMed/NCBI
3	Yang L, Wang J, Li J, Zhang H, Guo S, Yan M, Zhu Z, Lan B, Ding Y, Xu M, et al: Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol Cell Proteomics. 15:614–623. 2016. View Article : Google Scholar : PubMed/NCBI
4	Hu QY, Jiang H, Su J and Jia YQ: MicroRNAs as biomarkers for hepatocellular carcinoma: A diagnostic meta-analysis. Clin Lab. 59:1113–1120. 2013. View Article : Google Scholar : PubMed/NCBI
5	Smolle MA, Bullock MD, Ling H, Pichler M and Haybaeck J: Long non-coding rnas in endometrial carcinoma. Int J Mol Sci. 16:26463–26472. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kiang KM, Zhang XQ and Leung GK: Long non-coding RNAs: The key players in glioma pathogenesis. Cancers (Basel). 7:1406–1424. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fan ZY, Liu W, Yan C, Zhu ZL, Xu W, Li JF, Su L, Li C, Zhu ZG, Liu B and Yan M: Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer. Tumour Biol. 37:13265–13277. 2016. View Article : Google Scholar : PubMed/NCBI
8	Jin C, Shi W, Wang F, Shen X, Qi J, Cong H, Yuan J, Shi L, Zhu B, Luo X, et al: Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget. 7:51763–51772. 2016.PubMed/NCBI
9	Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt PM; QUADAS-2 Group, : QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 155:529–536. 2011. View Article : Google Scholar : PubMed/NCBI
10	Whiting P, Harbord R and Kleijnen J: No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol. 5:192005. View Article : Google Scholar : PubMed/NCBI
11	Lin R, Yan J, Liu W, Fan T and Tang L: The predictive value of cervical lymph node metastasis through sentinel lymph node biopsy in patients with oral cancer: A meta-analysis. J Cancer Res Ther. 12 Suppl:C256–C259. 2016. View Article : Google Scholar : PubMed/NCBI
12	Chu H and Guo H: A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics. 10:201–203. 2009. View Article : Google Scholar : PubMed/NCBI
13	Yang Z, Zhi Q, Wang D, Zhang L, Preston B, Brandon C, Kuang Y, Miao R, Shi Y and Guo X: Long non-coding RNA C21orF96 promotes the migration, invasion and lymph node metastasis in gastric cancer. Anticancer Agents Med Chem. 16:1101–1108. 2016. View Article : Google Scholar : PubMed/NCBI
14	Lü MH, Tang B, Zeng S, Hu CJ, Xie R, Wu YY, Wang SM, He FT and Yang SM: Long non-coding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene. 35:3524–3534. 2016. View Article : Google Scholar : PubMed/NCBI
15	Li DF, Yang MF, Shi SL, Du YL, Wang H, Zhou YL, Luo YL, Ren LL and Nie YQ: TM4SF5-CTD-2354A18.1-miR-4697-3P may play a key role in the pathogenesis of gastric cancer. Bratisl Lek Listy. 116:608–615. 2015.PubMed/NCBI
16	Du T, Zhang B, Zhang S, Jiang X, Zheng P, Li J, Yan M, Zhu Z and Liu B: Decreased expression of long non-coding RNA WT1-AS promotes cell proliferation and invasion in gastric cancer. Biochim Biophys Acta. 1862:12–19. 2016. View Article : Google Scholar : PubMed/NCBI
17	Xia H, Chen Q, Chen Y, Ge X, Leng W, Tang Q, Ren M, Chen L, Yuan D, Zhang Y, et al: The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget. 7:56209–56218. 2016.PubMed/NCBI
18	Zhang E, He X, Yin D, Han L, Qiu M, Xu T, Xia R, Xu L, Yin R and De W: Increased expression of long non-coding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57. Cell Death Dis. 7:e21092016. View Article : Google Scholar : PubMed/NCBI
19	Mei D, Song H, Wang K, Lou Y, Sun W, Liu Z, Ding X and Guo J: Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med Oncol. 30:7092013. View Article : Google Scholar : PubMed/NCBI
20	Sun W, Wu Y, Yu X, Liu Y, Song H, Xia T, Xiao B and Guo J: Decreased expression of long non-coding RNA AC096655.1–002 in gastric cancer and its clinical significance. Tumour Biol. 34:2697–2701. 2013. View Article : Google Scholar : PubMed/NCBI
21	Shao Y, Ye M, Jiang X, Sun W, Ding X, Liu Z, Ye G, Zhang X, Xiao B and Guo J: Gastric juice long non-coding RNA used as a tumor marker for screening gastric cancer. Cancer. 120:3320–3328. 2014. View Article : Google Scholar : PubMed/NCBI
22	Liu Z, Shao Y, Tan L, Shi H, Chen S and Guo J: Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol. 35:9613–9617. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhou X, Yin C, Dang Y, Ye F and Zhang G: Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 5:115162015. View Article : Google Scholar : PubMed/NCBI
24	Pang Q, Ge J, Shao Y, Sun W, Song H, Xia T, Xiao B and Guo J: Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol. 35:5441–5447. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhao Y, Guo Q, Chen J, Hu J, Wang S and Sun Y: Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: A clinical and in vitro investigation. Oncol Rep. 31:358–364. 2014.PubMed/NCBI
26	Chen WM, Huang MD, Kong R, Xu TP, Zhang EB, Xia R, Sun M, De W and Shu YQ: Antisense long non-coding RNA HIF1A-AS2 Is upregulated in gastric cancer and associated with poor prognosis. Dig dis Sci. 60:1655–1662. 2015. View Article : Google Scholar : PubMed/NCBI
27	Sun J, Song Y, Chen X, Zhao J, Gao P, Huang X, Xu H and Wang Z: Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer. Oncol Lett. 10:115–120. 2015.PubMed/NCBI
28	Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C, Ye H, Zhou B, Chen JJ and Chen P: Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol. 17:640–646. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sun XD, Huan C, Qiu W, Sun DW, Shi XJ, Wang CL, Jiang C, Wang GY and Lv GY: Clinical significance of UCA1 to predict metastasis and poor prognosis of digestive system malignancies: A meta-analysis. Gastroenterol Res Pract. 2016:37298302016. View Article : Google Scholar : PubMed/NCBI